与认知不受损的个体中的粉样蛋白阳性相关的症状集群
Lena Sannemann1, Claudia Bartels2, Frederic Brosseron3
1Department of Psychiatry, University of Cologne, Medical Faculty, Cologne, Germany.
Journal of Alzheimer's disease : JAD
|June 7, 2024
概括
阿尔茨海默病第二阶段涉及到微妙的认知能力下降. 一个有主观认知衰退和客观认知功能障碍的集群显示出更高的粉样蛋白阳性,表明早期阿尔茨海默氏症的病理.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 生物标志物 生物标志物
背景情况:
- 根据NIA-AA框架,阿尔茨海默病 (AD) 第二阶段是过渡阶段.
- 这个阶段包括微妙的认知衰退,主观认知衰退 (SCD) 和神经行为症状 (NPS).
研究的目的:
- 根据他们的症状,识别AD第二阶段的个体群.
- 调查这些症状集群与粉样蛋白阳性之间的关联.
主要方法:
- 利用了DELCODE队列中338名认知正常参与者的基线数据.
- 使用大脑脊髓液Aβ42/40比率评估粉样蛋白阳性 (A+).
- 评估了客观认知功能障碍 (OBJ),主观认知衰退 (SCD) 和神经行为症状 (NPS).
- 对组参与者进行了集群分析,并将AD生物标志物与集群进行了比较.
主要成果:
- 根据症状确定了三个不同的参与者群.
- 一个表现出客观认知功能障碍和主观认知衰退的集群具有最高的粉样蛋白阳性率 (47.6%).
- 患有SCD和NPS (26.6%A+) 和少数症状 (19.7%A+) 的群体没有显著增加粉样蛋白阳性.
- 与记忆相关的SCD和OBJ结合的参与者具有较低的Aβ42 / ptau181比率.
结论:
- 一个特定的集群,以客观认知功能障碍和主观认知衰退为特征,为粉样蛋白病理丰富.
- 这一发现强调了在过渡阶段内潜在的阿尔茨海默病早期指标.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.阿尔茨海默病的连续性是阿尔茨海默病的连续性NIA-AA第二阶段粉样蛋白是什么 粉样蛋白大脑脊髓液的生物标志物神经精神病症状 神经精神病症状在临床前的阿尔茨海默氏病.主观认知衰退 主观认知衰退更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
12:28Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
17.3K
相关概念视频
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
01:26Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
01:30Negative and Cognitive Symptoms of Schizophrenia
48
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
48
01:30Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110